Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Abstract Text:

Vanessa A Mitchell,Ruth Greenwood,Angelo Jayamanne,Christopher W Vaughan,

1. Although cannabinoid receptor agonists have analgesic activity in chronic pain states, they produce a spectrum of central cannabinoid CB(1) receptor-mediated motor and psychotropic side-effects. The actions of endocannabinoids, such as anandamide, are terminated by uptake and subsequent intracellular enzymatic degradation. In the present study, we examined the effect of acute administration of the anandamide transport inhibitor AM404 in rat models of chronic neuropathic and inflammatory pain. 2. Systemic administration of AM404 (10 mg/kg) reduced mechanical allodynia in the partial sciatic nerve ligation (PNL) model of neuropathic pain, but not in the complete Freund's adjuvant (CFA) model of inflammatory pain. 3. The effect of AM404 in the PNL model was abolished by coapplication with the selective cannabinoid CB(1) receptor antagonist AM251 (1 mg/kg). AM404 did not produce a reduction in motor performance in either the PNL or CFA models. 4. These findings suggest that acute administration of AM404 reduces allodynia in a neuropathic pain model via cannabinoid CB(1) receptor activation, without causing the undesirable motor disruption associated with cannabinoid receptor agonists.

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Publishing Authors By Initials

VA Mitchell,R Greenwood,A Jayamanne,CW Vaughan,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical and experimental pharmacology & physiolog

VOLUME: 34

Page Numbers: 1186-90

Journal Abbreviation: Clin. Exp. Pharmacol. Physiol.

ISSN: 0305-1870

DAY: 3

MONTH: Nov

YEAR: 2007

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 425076

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: metabolism

Chemical & Substance for Abstract: Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Information

Substance Name: anandamide

Registry Number: 94421-68-8

Grant and Affiliation Information for Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.

AFFILIATION: Pain Management Research Institute, Kolling Institute, Northern Clinical School, The University of Sydney, St Leonards, New South Wales, Australia.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Pharmacol Physiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models Related Publications

• ATP-Binding cassette cholesterol transporters and cardiovascular disease.
• Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
• Allergic problems in the upper respiratory tract, including the ear.
• Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization.
• Anemias of infancy and childhood.
• Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
• Bone marrow plasminogen activator inhibitor-1 influences the development of obesity.
• Central adiposity and risk of Barrett's esophagus.
• Dielectric behavior of linear polyelectrolytes.
• Dielectric behavior of polyelectrolytes II. The cylinder.
• Dielectric behavior of polyelectrolytes III. The role of counterion interactions.
• Disclosure of date/acquaintance rape: who reports and when.
• Epidemiology and pathogenesis of esophageal cancer.
• Extending Fitts' Law to manual obstacle avoidance.
• Homonataloin in Aloe species.
• Long-Term Experience With 5-alpha-Reductase Inhibitors.
• Long-Term Experience with 5-alpha-Reductase Inhibitors.
• Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity.
• Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency.
• Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
• NHS set for pound13m net surplus despite rising levels of debt.
• Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals.
• Population dynamics of Plasmodium sporogony.
• Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice.
• Regulation of the dopamine transporter by phosphorylation.
• Selective dorsal rhizotomy: long-term experience from Cape Town.
• Sexually mediated shedding of Myxobolus fallax spores during spermiation of Litoria fallax (anura).
• Survival differences by race in nasopharyngeal carcinoma.
• The position of the head and centre of mass during the front foot off-drive in skilled and less-skilled cricket batsmen.
• Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice.